Global Medical Director - Multiple Myeloma, Oncology
About the job
- MD, MBBS, PharmD, or PhD in a clinical or scientific discipline relevant to oncology, such as medical oncology, haematology, or tumour immunology.
- At least 5 years of Medical Affairs experience, including local operating company, regional, or global roles and hands-on leadership of pre-launch, peri-launch, and post-launch asset phases.
- Experience working with regulatory and clinical development strategies across early- and late-stage oncology development.
- A demonstrated track record leading complex matrix initiatives, managing multiple projects and budgets simultaneously, and influencing senior stakeholders.
- Serve as a key medical business leader for the assigned oncology asset or portfolio, accountable to the Global Medical Lead for strategy and execution.
- Represent the Chief Patient organisation as a medical business leader, applying oncology scientific expertise from early development through lifecycle management to improve patient and population outcomes.
- Lead or support development of the global disease and asset strategy, integrating scientific, clinical, and market insights to guide evidence priorities, communication narratives, product positioning, and evidence-generation strategy.
- Act as a primary interface with senior internal leaders and external stakeholders, including clinical experts, advocacy groups, regulators, and payors, to shape disease understanding and treatment paradigms.
- Partner with country medical and cross-functional teams to translate local insights into global plans and deliverables.
- Lead global medical operational planning for the asset, ensuring plans are externally focused, insight driven, and delivered on time and on budget across indications and geographies.
- Partner across research and development, real-world evidence, health outcomes, global product strategy, and country teams to identify and prioritize oncology evidence-generation needs.
- Develop scientific questions based on prioritized data gaps and work with data-generation leads to shape Phase 3b/4 and value/evidence plans.
- Review and approve Phase 3b/4 and value-evidence/health-outcomes studies within remit, ensuring scientific rigor and strategic alignment.
- Review investigator-sponsored study proposals for strategic alignment and scientific merit in liaison with research and development, safety, biostatistics, and other experts.
- Partner with Scientific Communications Leads and Integrated Medical Communications teams to align scientific narratives, publication strategy, and engagement tactics with the global oncology medical strategy.
- Define key scientific messages and provide oversight for integrated scientific communication plans, including congress strategy, medical education, digital engagement, and omnichannel content.
- Lead development and communication of asset newsflow, including data milestones, congress plans, and publication timelines.
- Develop a global network of external experts, including healthcare professionals, payors, patient representatives, and regulators, and collaborate with local operating company medical teams on advisory activities and initiatives to improve care pathways and outcomes.
- Provide medical signatory or approval for promotional and non-promotional materials, including congress and digital materials, as required by GSK Written Standards.
- Lead complex cross-functional initiatives supporting the oncology asset strategy, including launch excellence, lifecycle optimization, indication expansion, and access and reimbursement support.
- Provide thought leadership and strategic direction to anticipate challenges and opportunities in oncology treatment paradigms and evidence requirements.
- Act as a key partner and delegate to the Global Medical Lead, representing the Global Medical Lead in cross-functional forums and governance interactions.
- Inspire and motivate team members across the matrix organization, fostering collaboration, psychological safety, inclusion, and engagement without direct line-management accountability.
- Mentor junior medical-affairs professionals and support their development.
- Advanced clinical training or board certification in oncology or haematology.
- Global or above-country leadership experience for oncology assets, such as global medical lead, global medical director, or therapeutic-area lead.
- Strong interpersonal, verbal, and written communication skills in English, with the ability to simplify complex science for diverse audiences.
- Experience driving real-world evidence or health economics and outcomes research programs and shaping access and reimbursement in oncology.
- Experience working across multiple regions and major markets, including the United States, European Union, Japan, China, and emerging markets.
About the company
GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.
Company Size
10,001+
Company Stage
IPO
Headquarters
London, United Kingdom
Founded
1891
Get referred to GSK
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 5% to £8.4 billion, beating expectations.
- GSK launched a £1.9 billion savings plan to fund late-stage trials and margin expansion.
- Jemperli’s rectal-cancer data and Blenrep’s multiple-myeloma progress strengthen 2026 launch momentum.
What critics are saying
- Dresden’s 2027 closure threatens 641 jobs and risks union fights and severance costs.
- Camlipixant’s £1.3 billion write-down exposed brittle pipeline selection under Luke Miels.
- Dolutegravir patent expiry from 2028 to 2030 threatens margins and an existential HIV franchise hit.
What makes GSK unique
- Jemperli, Blenrep, and Exxentia give GSK differentiated oncology and immunology shots.
- GSK’s 62-asset pipeline and 25 late-stage studies target multiple high-value indications in 2026.
- Vaccine and specialty medicine scale support cash generation while Trelegy and Shingrix diversify revenue.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Remote Work Options
Flexible Work Hours
Paid Vacation
Paid Holidays
Hybrid Work Options
Wellness Program
Mental Health Support
Phone/Internet Stipend
Company News
Cambridgeshire hospitals to share electronic patient record. 27th September Cambridge University Hospitals (CUH) and Royal Papworth Hospital are joining forces to introduce a shared electronic patient record (EPR) system. The system will improve care across the Cambridge Biomedical Campus and beyond by helping the two NHS trusts share information and avoid duplication. Harvey McEnroe, Royal Papworth Hospital's chief operating officer and senior responsible officer for the EPR programme, said: "This is a huge step forward for its organisations and the patients Bubble CiTea serve. The partnership aims to support more joined-up patient care (Image: Royal Papworth Hospital) "We are grateful to NHS England, our integrated care board and all our partners for their support and collaboration in helping make our ambitions to create a shared electronic patient record a reality." The EPR will use CUH's Epic system, which has been in place since 2014, through the Epic Connect model. The model has already been used elsewhere in the UK to link neighbouring hospitals more closely. The rollout is expected to take just over a year and will involve both trusts and Epic Systems Corporation. Royal Papworth Hospital (Image: Royal Papworth Hospital) Harvey said: "This clinically led decision will transform the way we deliver care, strengthen collaboration between our hospitals, and enhance our research capabilities, benefiting patients and staff for years to come." Patients will get more joined-up care, with clinical teams able to see their complete information in one place. It should mean patients repeat themselves less and move more smoothly between services. Royal Papworth Hospital and Cambridge University Hospitals are working together (Image: Royal Papworth Hospital) Dr Sue Broster, chief medical officer at Cambridge University Hospitals, said: "This important development will improve the experience of patients receiving care across its two hospitals. "By bringing information together securely in one place, it will support smoother transitions, reduce duplication and help Bubble CiTea achieve its aim of patients only having to tell their story once. "It will also help ensure that care remains consistent and is delivered at the right time." The partnership comes as GSK plans a £400 million global research and development centre on the Cambridge Biomedical Campus, with around 1,000 scientists expected at the site by 2029.
GSK share price decline deepens as new CEO faces pipeline rebuild. The GSK share price decline has accelerated over the past six months, leaving investors who held £6,000 in the stock at that point with roughly £5,100 today, before dividends. The FTSE 100 pharmaceuticals group is down 15% over six months even as it reported solid underlying trading in its second-quarter results on 28 July. The Q2 figures showed turnover of £7,986m, up 6% at constant exchange rates, with year-to-date revenue reaching £15,502m, up 5% at constant exchange rates, according to GSK's own results release. Core operating margin for the quarter was 32.9%, up 1.1 percentage points at actual exchange rates. A £1.3bn write-down overshadows the trading beat. The headline numbers were harder to ignore. Total operating profit fell 75% in the quarter, driven by a £1.3bn impairment linked primarily to camlipixant, a drug in development that failed to meet expectations. Core operating profit, which strips out such charges, rose 7% to £2.8bn. New chief executive Luke Miels, who took over after Emma Walmsley's departure was announced in September 2025, also unveiled a three-year cost take-out programme targeting £1.9bn in savings. Alongside that, GSK plans to start more than 20 Phase III trials in 2026, up from around 10 previously expected, with the R&D portfolio covering 62 separate assets. Q2 operating cash flow was £2.9bn, roughly twice the first-quarter level, and free cash flow reached £2.0bn for the period. GSK share price decline in context: two decades of slim returns. The six-month drop sits within a longer pattern of underperformance. GSK's share price stood at around 1,500p in August 2006; it trades at 1,815p today, a gain of just 21% over two decades. R&D spending has risen sharply throughout that period, reaching £6.57bn last year, as the company tried and largely failed to convince investors it has the drugs to deliver growth. The dividend record has been similarly frustrating. The board froze the payout at 80p per share in 2015 and held it there for seven years. The Haleon demerger in July 2022 complicated matters further. GSK distributed the bulk of its stake in the Consumer Healthcare joint venture (which it had built with Pfizer) to shareholders, who received one Haleon share per GSK share held, before a share consolidation gave investors four new GSK shares for every five existing ones, according to GSK's corporate actions disclosure. Following the separation, Pfizer retained a 32% stake in Haleon while GSK kept 13.5%. The dividend fell to 57.75p per share after the demerger. The GSK dividend calendar shows the 2023 full-year total at 58p per share. The payout recovered to 66p last year. For 2026, GSK has guided to 70p per share. Full-year profit figures illustrate the uneven trajectory. GSK reported profits of £7.93bn in 2025, £6.01bn in 2024 (hit by multi-billion-pound Zantac settlement provisions), £6.75bn in 2023, £6.73bn in 2022, and £6.20bn in 2021. The 2025 number was boosted by strong growth in Specialty Medicines and Vaccines. GSK filed its 2025 Annual Report on Form 20-F with the SEC on 6 March 2026, covering the year ended 31 December 2025. Valuation and what comes next. GSK's shares trade on a price-to-earnings ratio of around 10.8, with a trailing dividend yield of 3.64%. The stock is up 30% over one year, lifted by the management change, but the six-month GSK share price decline has trimmed much of that gain. Miels is targeting more than £40bn in annual sales by 2031. For 2026, the company expects sales and core operating profit to land at the upper end of guidance ranges of 3% to 5% and 7% to 9% respectively. Patent expiries and pipeline replenishment remain the central tests. The cost programme and the step-up in Phase III activity are the clearest signals yet of how Miels intends to address them. Whether the 2031 sales target anchors the share price or fades into GSK's long history of missed milestones is the question investors will be weighing at the third-quarter update.
GSK reprimanded for lack of transparency in vaccine campaign case A British panel criticizes GSK's handling of its collaboration with health authorities on a shingles vaccination campaign. 25 September 2026at 11:39 Try MedWatch for 14 days - and get access to all content.
GSK plans to make up to 500 IT staff in Poznań redundant. The relocation of some IT services from Poznań to India illustrates how quickly global corporations today are reassessing costs, expertise, and the location of their technology infrastructure. September 24, 2026 GSK is planning a major reorganisation of its technical operations in Poznań, with some of the tasks currently carried out there set to be transferred to India. According to information from epoznan.pl, the changes could affect more than 500 IT staff. Hieronim Marut, chairman of the NSZZ "Solidarność" trade union at GSK, confirmed the planned redundancies to the local media. The union has announced that it will enter into negotiations regarding the terms of the redundancies. The decision forms part of a much larger restructuring programme at GSK. In July, the company announced a three-year plan to optimise costs and its organisational structure. By 2029, the company aims to achieve annual savings of £1.9 billion, with restructuring costs estimated at £2.4 billion. GSK highlights, amongst other things, the streamlining of support services, the re-engineering of processes and the wider use of technology and AI. The savings are largely intended to fund investment in research and development and the late stages of new drug development. At the same time, GSK maintains its target of exceeding £40 billion in sales by 2031. For the Polish labour market, however, there is more at stake than just the scale of the redundancies. For years, Poznań has benefited from the growth of global service and technology centres, established in Poland thanks to the wide availability of specialists and relatively competitive costs. Increasingly, this model is being reassessed. Standardised processes can be relocated to cheaper locations, automated or concentrated in a few larger centres. GSK is not alone in this respect. In June, HSBC began restructuring its service centre in Kraków. Eurofound points out that the changes affect, amongst other areas, IT and cybersecurity, and that some processes are also set to be transferred to India. This does not spell the end of Poland's centre of excellence sector, but it may alter its structure. Teams responsible for specialist technologies, architecture, data, cybersecurity and product development are gaining greater value, whilst simpler services that are easier to standardise remain more susceptible to relocation and automation. At the same time, GSK has stated that Poznań will remain one of the company's two multifunctional Global Centres of Competence. However, following the restructuring, the scale of its operations and its employment profile may be significantly different from what they have been to date.
GSK targets £40B sales as oncology push and £1.9B savings plan take shape. GSK (NYSE:GSK) Chief Financial Officer Julie Brown outlined the company's growth strategy, launch priorities and cost-savings plans during a discussion with Bank of America analyst Sachin Jain following the company's recent capital markets day. Brown said GSK's strategic portfolio review identified seven major assets across roughly 18 indications for accelerated development, with particular emphasis on oncology. The company also announced a simplification program designed to generate £1.9 billion in savings, with most of the savings intended to fund pipeline investment. Part of the savings is expected to support margins during the period when GSK faces patent expirations for dolutegravir-based HIV medicines. Brown said the company expects margins to be stable to improving from 2028 through 2030, despite the anticipated impact from patent losses. She said GSK has established a track record of investing in research and development while improving productivity, citing expected sales growth above 7%, profit growth above 11% and a margin improvement of more than 500 basis points over the 2021-to-2026 period. Oncology a key difference in revenue expectations. Brown said the largest difference between GSK's outlook of more than £40 billion in sales and consensus estimates of £36.4 billion is in oncology. She cited the company's antibody-drug conjugate portfolio, including assets referred to as MORES and RISRES, as well as BLENREP and Jemperli. She noted that GSK's forecasts include probability-of-technical-and-regulatory-success adjustments. Brown also said consensus may be slower to recognize newer products, including HIV innovations and Excentia. GSK expects specialty medicines to provide a natural lift to profitability as the business mix evolves. Specialty products accounted for just over 40% of the business, compared with roughly one-third when Brown joined in early 2023, and are expected to exceed 50% by 2031, she said. The company is seeking to reduce selling, general and administrative expenses through productivity efforts while increasing R&D investment. Launch dynamics for Excentia and BLENREP. Brown said Excentia, a twice-yearly biologic treatment for severe asthma, has faced a reimbursement and administrative hurdle in the United States because of its upfront cost under the "buy-and-bill" system. The product received a J-code on July 1, but Brown said the related administrative process only began to flow through insurer systems in recent weeks. "We would expect, having removed one of the largest barriers," prescribing conditions to improve entering the fourth quarter, Brown said. GSK plans to provide an update on payer coverage and its patient access program with third-quarter results. For BLENREP, Brown reiterated that GSK intends to "go slow to go big." She said the multiple myeloma treatment has strong clinical data, including a reduction in risk of death and improved progression-free survival, but requires careful monitoring of eye-related side effects. BLENREP is administered as a 30-minute infusion and could address an unmet need among community-treated patients, she said. Outside the U.S., BLENREP has registrations in more than 50 countries and is generally used in the second-line setting, while its U.S. label is for third-line use. Brown said that difference means the U.S. patient population is generally older and frailer, requiring a different launch approach. Hepatitis B and Nuvalent launches. Brown described bepirovirsen as a potentially transformational opportunity in hepatitis B. She said the treatment produced a functional cure in 19% of patients and lowered surface antigen levels in additional patients. GSK has approval in Japan, where pricing negotiations are under way, and expects an approval decision in China around the middle of next year. She identified China, the U.S. and Japan as the main commercial markets for the product. China has an estimated 75 million people affected by hepatitis B, she said, though GSK did not provide country-by-country sales timing or guidance. Brown also highlighted launches from GSK's Nuvalent acquisition. She said idasanlimab had been approved ahead of its PDUFA date and that launch preparations were under way. Niltalisertib, a fourth-generation ALK therapy, has a PDUFA date toward the end of November for an initial second-line indication. GSK expects a potential first-line opportunity to emerge around 2029, with recruitment progressing well in ongoing trials. Headwinds and business development capacity. For 2027, Brown identified TRELEGY as GSK's principal headwind because of pricing implications associated with the Inflation Reduction Act. She said the effect has been incorporated into company forecasts but did not quantify it. She also cited tougher comparisons for products such as SHINGRIX, while noting that vaccination penetration outside the U.S. remains materially below U.S. levels. Brown said GSK continues to evaluate external business-development opportunities alongside internal pipeline programs. Following the Nuvalent acquisition, the company's pro forma net debt-to-EBITDA ratio is just under two times, she said. GSK also expects to generate more than £10 billion in cash from operations this year. Brown said future deal decisions will be based on the quality of an asset rather than whether it is late-stage or early-stage. About GSK (NYSE:GSK). GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world. GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV). The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.